MEX3A regulates Lgr5+ stem cell maintenance in the developing intestinal epithelium.
Saved in:
| Title: | MEX3A regulates Lgr5+ stem cell maintenance in the developing intestinal epithelium. |
|---|---|
| Authors: | Pereira B; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal., Amaral AL; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal., Dias A; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal., Mendes N; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal., Muncan V; Department of Gastroenterology and Hepatology, Amsterdam UMC, Tytgat Institute, University of Amsterdam, Amsterdam, The Netherlands., Silva AR; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal., Thibert C; Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France., Radu AG; Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France., David L; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.; FMUP-Faculty of Medicine, University of Porto, Porto, Portugal., Máximo V; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.; FMUP-Faculty of Medicine, University of Porto, Porto, Portugal., van den Brink GR; Department of Gastroenterology and Hepatology, Amsterdam UMC, Tytgat Institute, University of Amsterdam, Amsterdam, The Netherlands.; Medicines Research Center, GSK, Stevenage, UK., Billaud M; Clinical and Experimental Model of Lymphomagenesis, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Almeida R; i3S - Institute for Research and Innovation in Health (Instituto de Investigação e Inovação em Saúde), University of Porto, Porto, Portugal.; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.; FMUP-Faculty of Medicine, University of Porto, Porto, Portugal.; Biology Department, Faculty of Sciences, University of Porto, Porto, Portugal. |
| Source: | EMBO reports [EMBO Rep] 2020 Apr 03; Vol. 21 (4), pp. e48938. Date of Electronic Publication: 2020 Feb 13. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 100963049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-3178 (Electronic) Linking ISSN: 1469221X NLM ISO Abbreviation: EMBO Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1469-3178 |
|---|---|
| DOI: | 10.15252/embr.201948938 |
